



GEDEON RICHTER

Celebrating 125 years

## Change in the Board of Directors of Richter

**Budapest, 29 June 2026** - Gedeon Richter Plc. („Richter”) hereby announces that Dr. Péter Cserháti, member of the Board of Directors, has resigned from his position on the Board with effect from 1 July 2026, in view of his appointment to perform advisory duties as a ministerial advisor within the healthcare administration.

### About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at [www.gedeonrichter.com](http://www.gedeonrichter.com)

### For further information:

Investors: Róbert Réthy, CFA

+36 20 342 2555

Media: Zsuzsa Beke

+36 20 916 4507

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary

Phone: +36 1 431 4000 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944

EU Community VAT Identification No: HU 10484878 • [www.gedeonrichter.com](http://www.gedeonrichter.com)